AMEX:ISR

Stock Analysis Report

Executive Summary

IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States.

Snowflake

Fundamentals

High growth potential with adequate balance sheet.


Similar Companies

Share Price & News

How has IsoRay's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-2.8%

ISR

1.6%

US Biotechs

0.4%

US Market


1 Year Return

-36.7%

ISR

-7.7%

US Biotechs

6.9%

US Market

Return vs Industry: ISR underperformed the US Biotechs industry which returned -7.7% over the past year.

Return vs Market: ISR underperformed the US Market which returned 6.9% over the past year.


Shareholder returns

ISRIndustryMarket
7 Day-2.8%1.6%0.4%
30 Day-15.6%-2.9%-1.1%
90 Day-23.3%-1.7%-0.5%
1 Year-36.7%-36.7%-6.9%-7.7%9.3%6.9%
3 Year-52.3%-52.3%14.7%10.7%45.8%36.4%
5 Year-82.5%-82.5%-2.3%-7.0%62.9%45.1%

Price Volatility Vs. Market

How volatile is IsoRay's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is IsoRay undervalued compared to its fair value and its price relative to the market?

2.72x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ISR's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ISR's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ISR is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: ISR is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ISR's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ISR is overvalued based on its PB Ratio (2.7x) compared to the US Biotechs industry average (2.6x).


Next Steps

Future Growth

How is IsoRay forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

60.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ISR is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.7%).

Earnings vs Market: ISR is forecast to become profitable over the next 3 year, which is considered above average market growth.

High Growth Earnings: ISR's loss is forecast to worsen by 0% next year.

Revenue vs Market: ISR's revenue (28.5% per year) is forecast to grow faster than the US market (7.2% per year).

High Growth Revenue: ISR's revenue (28.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ISR's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has IsoRay performed over the past 5 years?

-6.0%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: ISR is unprofitable, and losses have increased over the past 5 years at a rate of -6% per year.

Accelerating Growth: Unable to compare ISR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ISR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (78.4%).


Return on Equity

High ROE: ISR has a negative Return on Equity (-66.98%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: ISR is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: ISR is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is IsoRay's financial position?


Financial Position Analysis

Short Term Liabilities: ISR's short term assets ($7.3M) exceeds its short term liabilities ($1.1M)

Long Term Liabilities: ISR's short term assets (7.3M) exceeds its long term liabilities (621.0K)


Debt to Equity History and Analysis

Debt Level: ISR is debt free.

Reducing Debt: ISR has not had any debt for past 5 years.


Balance Sheet

Inventory Level: ISR has a high level of physical assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if ISR's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ISR has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: ISR has less than a year of cash runway if free cash flow continues to reduce at historical rates of -4.4% each year


Next Steps

Dividend

What is IsoRay's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.0%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate ISR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate ISR's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if ISR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ISR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ISR's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of IsoRay's salary, the management and board of directors tenure and is there insider trading?

1.1yrs

Average management tenure


CEO

Lori Holmes-Woods (57yo)

1.3yrs

Tenure

US$416,524

Compensation

Ms. Lori A. Holmes-Woods has been Chief Executive Officer since December 12, 2018 and its Director at IsoRay, Inc. since June 4, 2018 and served as its Interim Chief Executive Officer since June 4, 2018 un ...


CEO Compensation Analysis

Compensation vs. Market: Lori has recently become CEO, making it difficult to compare their total compensation against companies of similar size in the US market.

Compensation vs Earnings: Lori's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

1.1yrs

Average Tenure

49yo

Average Age

Experienced Management: ISR's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.


Board Age and Tenure

2.5yrs

Average Tenure

58yo

Average Age

Experienced Board: ISR's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$10,00026 Nov 18
Alan Hoffmann
EntityIndividual
Role
Member of the Board of Directors
Director
Shares25,000
Max PriceUS$0.40
BuyUS$1,70321 Nov 18
Mark Austin
EntityIndividual
Role
Chief Accounting Officer
Controller
Shares4,283
Max PriceUS$0.40
BuyUS$4,00016 Nov 18
William Cavanagh
EntityIndividual
Role
Senior Key Executive
Chief Research & Development Officer
Shares10,000
Max PriceUS$0.40
BuyUS$1,00515 Nov 18
Mark Austin
EntityIndividual
Role
Chief Accounting Officer
Controller
Shares2,452
Max PriceUS$0.41
BuyUS$12,90015 Nov 18
Philip Vitale
EntityIndividual
Role
Member of the Board of Directors
Director
Shares30,000
Max PriceUS$0.43
BuyUS$51,73115 Nov 18
Lori Holmes-Woods
EntityIndividual
Role
Chief Executive Officer
CEO & Director
Shares130,000
Max PriceUS$0.40

Ownership Breakdown


Management Team

  • Lori Holmes-Woods (57yo)

    CEO & Director

    • Tenure: 1.3yrs
    • Compensation: US$416.52k
  • Jonathan Hunt (52yo)

    CFO & Co-Principal Financial Officer

    • Tenure: 0.8yrs
    • Compensation: US$166.02k
  • Bill Cavanagh (53yo)

    Chief Research & Development Officer

    • Tenure: 0.7yrs
    • Compensation: US$309.71k
  • Krista Cline (37yo)

    Director of Operations & Corporate Secretary

    • Tenure: 0yrs
  • Michael Krachon (48yo)

    Vice President of Sales & Marketing

    • Tenure: 3.6yrs
    • Compensation: US$326.83k
  • Jennifer Streeter (49yo)

    Interim COO & VP of Human Resources

    • Tenure: 0.3yrs
  • Mark Austin (32yo)

    Controller

    • Tenure: 2.3yrs

Board Members

  • Mike McCormick (56yo)

    Chairman of the Board

    • Tenure: 1.3yrs
    • Compensation: US$65.61k
  • Philip Vitale (73yo)

    Director

    • Tenure: 5.8yrs
    • Compensation: US$65.61k
  • Lori Holmes-Woods (57yo)

    CEO & Director

    • Tenure: 1.3yrs
    • Compensation: US$416.52k
  • Alan Hoffmann (59yo)

    Director

    • Tenure: 3.8yrs
    • Compensation: US$65.61k

Company Information

IsoRay, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: IsoRay, Inc.
  • Ticker: ISR
  • Exchange: AMEX
  • Founded: 1983
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$20.890m
  • Shares outstanding: 67.39m
  • Website: https://www.isoray.com

Number of Employees


Location

  • IsoRay, Inc.
  • 350 Hills Street
  • Suite 106
  • Richland
  • Washington
  • 99354
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ISRAMEX (NYSE MKT LLC)YesCommon StockUSUSDAug 2005

Biography

IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the Unit ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/21 00:01
End of Day Share Price2019/10/18 00:00
Earnings2019/06/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.